Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced a new $50 million stock repurchase program authorized by the Board, effective through March 31, 2027, replacing a prior authorization that expired March 27, 2026.

The prior program allowed up to $50 million; the company repurchased $24.8 million under that plan. Repurchases may occur on the open market or in privately negotiated transactions and may be suspended at any time. The company had approximately 52 million shares outstanding as of February 19, 2026.

Positive

• $50M repurchase authorization through March 31, 2027
• Board signals confidence in cash flow and capital allocation
• Repurchases may reduce shares outstanding and support EPS

Negative

• Prior authorization repurchased only $24.8M, below prior limit
• Program may be suspended or discontinued at any time

Key Figures

New buyback authorization: $50 million Prior buyback authorization: $50 million Repurchases completed: $24.8 million +5 more

8 metrics

New buyback authorization $50 million Repurchase capacity through March 31, 2027

Prior buyback authorization $50 million Program running through March 27, 2026

Repurchases completed $24.8 million Shares repurchased under prior authorization in 2025

Shares outstanding 52 million shares Common stock outstanding as of February 19, 2026

Prior buyback window end March 27, 2026 End date of previous $50M program

New buyback window end March 31, 2027 End date of new $50M repurchase program

Current share price $11.01 Price at time of article, up 0.46% on day

52-week range $4.02 – $14.06 Price vs. low and high before buyback news

Market Reality Check

Price: $8.15 Vol: Volume 1,069,606 is 1.71x...

high vol

$8.15 Last Close

Volume Volume 1,069,606 is 1.71x the 20-day average of 627,162, indicating elevated interest ahead of the buyback. high

Technical Shares at $11.01 are trading above the $9.19 200-day MA and 21.69% below the $14.06 52-week high.

Peers on Argus

EBS is up 0.46% with elevated volume, while only one scanned peer (ETON) shows m...

1 Down

EBS is up 0.46% with elevated volume, while only one scanned peer (ETON) shows momentum and is down 1.45%, pointing to a stock-specific reaction rather than a sector-wide move.

Previous Buybacks Reports

1 past event · Latest: Mar 31 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Mar 31	Stock buyback launch	Positive	+4.3%	Board authorized up to $50M stock repurchase as part of turnaround plan.

Pattern Detected

Limited history, but the prior $50M buyback announcement on Mar 31, 2025 saw a positive 4.29% next-day move, supporting constructive sentiment around repurchase authorizations.

Recent Company History

This announcement extends Emergent’s capital return efforts, replacing a prior authorization that also allowed up to $50 million of buybacks. In 2025, the company repurchased $24.8 million of shares under that plan. Historically, similar buyback news on Mar 31, 2025 coincided with a positive 4.29% price reaction, reflecting investor support for repurchases within the broader multi-year transformation and balance sheet improvement narrative.

Historical Comparison

+4.3% avg move · In the past year, EBS announced one prior buyback authorization, which saw an average next-day move ...

buybacks

+4.3%

Average Historical Move buybacks

In the past year, EBS announced one prior buyback authorization, which saw an average next-day move of 4.29%. Today’s repurchase plan closely mirrors that earlier program.

The company renewed its buyback capacity at $50 million, extending the program’s end date from March 27, 2026 to March 31, 2027 while continuing its transformation strategy.

Market Pulse Summary

This announcement details a new authorization to repurchase up to $50 million of common stock throug...

Analysis

This announcement details a new authorization to repurchase up to $50 million of common stock through March 31, 2027, replacing a prior $50 million program under which $24.8 million of shares were bought back. With about 52 million shares outstanding, the move ties into the company’s multi-year transformation and capital allocation strategy. Investors may watch actual repurchase activity, cash flow trends, and debt reduction updates to gauge how this program supports longer-term value creation.

Key Terms

stock repurchase program, common stock, insider trading policy

3 terms

stock repurchase program financial

"Emergent BioSolutions Announces New $50 Million Stock Repurchase Program"

A stock repurchase program is when a company buys back its own shares from the market. This can make each remaining share more valuable and shows that the company believes its stock is a good investment. It’s like a business treating its shares like a limited resource, hoping to boost confidence and share prices.

common stock financial

"repurchase of up to $50 million of the company’s common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

insider trading policy regulatory

"consistent with its insider trading policy"

A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.

AI-generated analysis. Not financial advice.

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares.

“In 2025, we were able to return value to shareholders through share repurchases as we continued to make progress on our multi-year transformation,” said Joe Papa, president and CEO of Emergent. “This new approval reflects the Board of Directors’ confidence in our ability to generate strong, sustainable cash flow and execute our capital allocation priorities for 2026 focused on growth, reducing debt and enabling long-term value creation for our shareholders.”

Stock repurchases under the newly authorized program may be made from time to time on the open market or in privately negotiated transactions. The timing and amount of any shares repurchased will be determined by the company’s management based on its evaluation of market conditions and other factors, including the market price of the company’s common shares, macroeconomic environment and other investment opportunities, consistent with its insider trading policy. The repurchase program may be suspended or discontinued at any time.

The company had approximately 52 million shares of common stock outstanding as of February 19, 2026.

About Emergent BioSolutions   
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.    

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives, acquisitions and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “confident,” “commit,” “forecast,” “future,” “outlook,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements are based on our current intentions, beliefs, assumptions and expectations regarding future events based on information that is currently available. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any such forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

What did Emergent BioSolutions (EBS) announce on February 26, 2026 about buybacks?

They authorized a new $50 million share repurchase program through March 31, 2027. According to the company, the authorization replaces a prior $50 million program and sets repurchase timing and amounts at management's discretion.

How much stock did Emergent repurchase under the prior authorization ending March 27, 2026?

Emergent repurchased $24.8 million of common stock under the prior authorization. According to the company, that amount reflects buybacks executed prior to the new $50 million authorization announcement.

How will the new $50 million EBS buyback be executed and when does it expire?

Repurchases may be made on the open market or via private transactions and may be suspended. According to the company, the authorization is effective through March 31, 2027.

How many shares of Emergent (EBS) were outstanding as of February 19, 2026?

The company reported approximately 52 million shares outstanding as of February 19, 2026. According to the company, this share count frames the potential per‑share impact of repurchases.

Does the $50 million repurchase program guarantee a set number of shares will be bought by EBS?

No, the program does not guarantee a specific share count or timing for repurchases. According to the company, management will determine timing and amounts based on market conditions and other factors.

What reasons did Emergent give for approving the new $50 million buyback program?

The board cited confidence in the company's ability to generate sustainable cash flow and capital allocation priorities. According to the company, priorities include growth, reducing debt, and enabling long‑term shareholder value.